More importantly, the inhibition of SMYD2 could be a very efficient therapeutic strategy for BC and HGSOC; however, more specific inhibitors should be developed, and multicenter clinical trials should be performed to validate this hypothesis. This evidence concerns the gene SMYD2 and breast cancer.